ArticleJournal of thoracic disease2025
Comparison of the short-term efficacy and safety of surgical operation of neoadjuvant sintilimab and camrelizumab, both in combination with chemotherapy in the treatment of resectable non-small cell lung cancer: a single-center retrospective cohort study.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Camrelizumab-induced intranasal hemangioma in a patient with hepatocellular carcinoma: a case report.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In recent years, neoadjuvant immunotherapy combined with chemotherapy has shown enhanced therapeutic efficacy and favorable surgical safety profile in the treatment of resectable non-small cell lung cancer (NSCLC). Currently, there has been no academic research that directly compares the efficacy of two different immune checkpoint inhibitors (ICIs). This study aims to evaluate the differences of the short-term efficacy and surgery-related safety of two different ICIs (sintilimab and camrelizumab), in conjunction with chemotherapy and followed by radical surgical resection in patients diagnosed with resectable NSCLC. Methods: This is a single-center retrospective cohort study involving patients. All patients diagnosed with NSCLC at Tangdu Hospital between June 2018 and March 2024, who received neoadjuvant therapy involving programmed cell death protein-1 (PD-1) inhibitors (specifically sintilimab or camrelizumab) in combination with chemotherapy and followed underwent surgical interventions, were consecutively enrolled in the study. Subsequently, in order to control confounding variables as much as possible, we innovatively employed two novel matching methods based on baseline characteristics: the 1:1 propensity score matching (PSM) method and the inverse treatment probability weighting (IPTW). We compare the efficacy and surgical safety of two different ICIs for patients with resectable NSCLC. Results: In total, 239 patients were enrolled, including 134 patients in the sintilimab group (SG) and 105 in the camrelizumab group (CG). Before PSM, the pathological complete response (pCR) rate did not differ between the SG and CG groups (42.5% Conclusions: In the neoadjuvant chemoimmunotherapy treatment of resectable NSCLC, sintilimab and camrelizumab demonstrated comparable short-term efficacy and surgical safety when administered in conjunction with chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.